Experts are excitedly focused on retatrutide, a innovative medication developed by Eli Lilly, as a possible breakthrough in body management. Unlike many previous approaches, retatrutide is a dual -action receptor targeting simultaneously GLP-1 and GIP, substances that affect hunger and blood glu